Jefferies Invites Expert to Discuss the VBA Medical Exam Program and LDOS Rebid Implications

Overview

This document is not a traditional in-depth financial modeling report, but rather an invitation to an expert call organized by Jefferies. The call focuses on the VBA Medical Exam program, with guest Hector Del Pozo bringing experience in home health, hospice, healthcare network expansion, and clinical operations. The report seeks to use the expert discussion to understand the program's services, vendor structure, service-quality measurement, revenue drivers, unit economics, pricing, margins, and Leidos Holdings' (LDOS) position in the related contract rebid.

Core views

The core view is that the VBA Medical Exam program may have business and competitive significance for LDOS, and investors need to understand its contract structure, service-quality metrics, vendor responsibilities, and rebid cadence. The report provides no new definitive investment conclusion or price target, but the disclosures show LDOS rated HOLD at a current price of $107.18.

Analysis framework

The analysis primarily relies on expert interviews to examine the VBA Medical Exam program's services, vendors, quality assessment mechanisms, and differences in revenue drivers, unit economics, pricing, and margins compared with government and healthcare services businesses. It also assesses the potential implications of LDOS's position in the competitive landscape and rebid.

Methodology notes

• Expert interviewExpert call

  Obtain qualitative, program-level information through interviews with experts who have relevant healthcare services and business development experience.

  The report schedules Hector Del Pozo for a 60-minute call to discuss the VBA Medical Exam program's services, vendors, quality measurement, business model, and the impact of the LDOS rebid.

• Valuation methodRelative valuation and multi-metric valuation

  Jefferies discloses that its price-target methodology may include EV/EBITDA, EPS, FCF yield, DCF, P/E, and P/FCF.

  The document states that a blended price target may be based on discounts to market multiples for 2026E EV/EBITDA, 2026E EPS, and 2026E FCF yield, but this invitation document does not provide a new price target for LDOS.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Leidos Holdings (LDOS)

  Company discussed as a potential competitor or vendor related to the VBA Medical Exam program

  Strengths

  The report focuses on LDOS's position in the VBA competitive landscape, indicating a business connection to the program that is relevant to investors.

  Weaknesses

  The document does not disclose LDOS's specific share, contract value, margin, or probability of winning the rebid for the program.

  Comparison

  The report plans to compare the VBA Medical Exam program with other government and healthcare services businesses in terms of revenue drivers, unit economics, pricing, and margins.

  Risks

  The rebid outcome, timing, customer concentration, contract mix, and integration issues may affect the investment assessment.

Key data

• Call time2026-07-09 2:00 PM ETThe report states that the call will last 60 minutes.
• Expert guestHector Del PozoCurrently Executive Director at Bridge Home Health & Hospice; previously Head of Business Development at AccentCare, with experience in healthcare network expansion and clinical operations.
• Main discussion topicsVBA Medical Exam program, vendor landscape, service quality, revenue drivers, unit economics, pricing, margins, LDOS rebid implicationsThese topics form the framework for the call.
• Company mentionedLeidos Holdings (LDOS)The disclosure page lists LDOS at a price of $107.18 with a HOLD rating.
• Jefferies rating distributionBUY 62.51%, HOLD 32.89%, UNDERPERFORM 4.59%From the report's Distribution of Ratings table.

Impact & implications

From an investment perspective, the call may help investors assess LDOS's competitive position in VBA Medical Exam-related contracts, contract rebid risks, revenue and margin characteristics, and the differences in economics between this program and traditional government or healthcare services businesses. Since the document itself provides no new financial forecasts or price target, its impact is more focused on information gathering and risk identification than on directly changing the valuation conclusion.

Risks

• Customer concentration risk.
• Contract mix change risk.
• Integration risk.
• Uncertainty surrounding the outcome and timing of the VBA Medical Exam program rebid.
• The report is primarily an invitation to an expert call and lacks full financial forecasts, a price target, and quantitative sensitivity analysis.

What to watch

• The service scope and vendor list for the VBA Medical Exam program.
• How program service levels and service quality are measured.
• Revenue drivers, unit economics, pricing, and margins.
• LDOS's position in the VBA competitive landscape.
• The upcoming rebid outcome, potential scenarios, and timing.